AAAAAA

   
Results: 1-11 |
Results: 11
FACTOR-V-LEIDEN AND THE PROTHROMBIN GENE MUTATION - 2 COMMON GENETIC-DEFECTS ASSOCIATED WITH THROMBOSIS
Authors: KUJOVICH JL GOODNIGHT SH
Citation: Jl. Kujovich et Sh. Goodnight, FACTOR-V-LEIDEN AND THE PROTHROMBIN GENE MUTATION - 2 COMMON GENETIC-DEFECTS ASSOCIATED WITH THROMBOSIS, Western journal of medicine, 168(6), 1998, pp. 524-525
COLLEGE-OF-AMERICAN-PATHOLOGISTS CONFERENCE XXXI ON LABORATORY MONITORING OF ANTICOAGULANT-THERAPY - THE CLINICAL USE AND LABORATORY MONITORING OF LOW-MOLECULAR-WEIGHT HEPARIN, DANAPAROID, HIRUDIN AND RELATED-COMPOUNDS, AND ARGATROBAN
Authors: LAPOSATA M GREEN D VANCOTT EM BARROWCLIFFE TW GOODNIGHT SH SOSOLIK RC
Citation: M. Laposata et al., COLLEGE-OF-AMERICAN-PATHOLOGISTS CONFERENCE XXXI ON LABORATORY MONITORING OF ANTICOAGULANT-THERAPY - THE CLINICAL USE AND LABORATORY MONITORING OF LOW-MOLECULAR-WEIGHT HEPARIN, DANAPAROID, HIRUDIN AND RELATED-COMPOUNDS, AND ARGATROBAN, Archives of pathology and laboratory medicine, 122(9), 1998, pp. 799-807
UPDATE IN HEMATOLOGY
Authors: GOODNIGHT SH FEINSTEIN DI
Citation: Sh. Goodnight et Di. Feinstein, UPDATE IN HEMATOLOGY, Annals of internal medicine, 128(7), 1998, pp. 545-551
ACUTE PROMYELOCYTIC LEUKEMIA IN THE ALL-TRANS-RETINOIC ACID ERA
Authors: DELOUGHERY TG GOODNIGHT SH
Citation: Tg. Deloughery et Sh. Goodnight, ACUTE PROMYELOCYTIC LEUKEMIA IN THE ALL-TRANS-RETINOIC ACID ERA, Medical oncology, 13(4), 1996, pp. 233-240
PROSPECTIVE COMPARISON OF INFRAINGUINAL BYPASS-GRAFTING IN PATIENTS WITH AND WITHOUT ANTIPHOSPHOLIPID ANTIBODIES
Authors: LEE RW TAYLOR LM LANDRY GJ GOODNIGHT SH MONETA GL EDWARDS JR YEAGER RA PORTER JM
Citation: Rw. Lee et al., PROSPECTIVE COMPARISON OF INFRAINGUINAL BYPASS-GRAFTING IN PATIENTS WITH AND WITHOUT ANTIPHOSPHOLIPID ANTIBODIES, Journal of vascular surgery, 24(4), 1996, pp. 524-531
INVASIVE LINE PLACEMENT IN CRITICALLY ILL PATIENTS - DO HEMOSTATIC DEFECTS MATTER
Authors: DELOUGHERY TG LIEBLER JM SIMONDS V GOODNIGHT SH
Citation: Tg. Deloughery et al., INVASIVE LINE PLACEMENT IN CRITICALLY ILL PATIENTS - DO HEMOSTATIC DEFECTS MATTER, Transfusion, 36(9), 1996, pp. 827-831
ANTIPLATELET THERAPY WITH ASPIRIN - FROM CLINICAL-TRIALS TO PRACTICE
Authors: GOODNIGHT SH
Citation: Sh. Goodnight, ANTIPLATELET THERAPY WITH ASPIRIN - FROM CLINICAL-TRIALS TO PRACTICE, Thrombosis and haemostasis, 74(1), 1995, pp. 401-405
PREDISPOSITION TO THROMBOSIS BY A FACTOR-V MUTATION CAUSING HEREDITARY RESISTANCE TO ACTIVATED PROTEIN-C
Authors: PRESS RD GOODNIGHT SH
Citation: Rd. Press et Sh. Goodnight, PREDISPOSITION TO THROMBOSIS BY A FACTOR-V MUTATION CAUSING HEREDITARY RESISTANCE TO ACTIVATED PROTEIN-C, Western journal of medicine, 162(5), 1995, pp. 450-452
THERAPEUTIC USE OF N-3 FATTY-ACIDS FOR VASCULAR-DISEASE AND THROMBOSIS
Authors: GOODNIGHT SH CAIRNS JA
Citation: Sh. Goodnight et Ja. Cairns, THERAPEUTIC USE OF N-3 FATTY-ACIDS FOR VASCULAR-DISEASE AND THROMBOSIS, Chest, 108(4), 1995, pp. 302-304
ANTIPHOSPHOLIPID ANTIBODIES IN VASCULAR-SURGERY PATIENTS - A CROSS-SECTIONAL STUDY
Authors: TAYLOR LM CHITWOOD RW DALMAN RL SEXTON G GOODNIGHT SH PORTER JM
Citation: Lm. Taylor et al., ANTIPHOSPHOLIPID ANTIBODIES IN VASCULAR-SURGERY PATIENTS - A CROSS-SECTIONAL STUDY, Annals of surgery, 220(4), 1994, pp. 544-551
ANTIPLATELET THERAPY .2.
Authors: GOODNIGHT SH COULL BM MCANULTY JH TAYLOR LM
Citation: Sh. Goodnight et al., ANTIPLATELET THERAPY .2., Western journal of medicine, 158(5), 1993, pp. 506-514
Risultati: 1-11 |